A novel model of cancer drug resistance: oncosomal release of cytotoxic and antibody-based drugs

Takanori Eguchi, Eman Ahmed Taha, Stuart K. Calderwood, Kisho Ono

Research output: Contribution to journalReview article


Extracellular vesicles (EVs), such as exosomes or oncosomes, often carry oncogenic molecules derived from tumor cells. In addition, accumulating evidence indicates that tumor cells can eject anti-cancer drugs such as chemotherapeutics and targeted drugs within EVs, a novel mechanism of drug resistance. The EV-releasing drug resistance phenotype is often coupled with cellular dedifferentiation and transformation in cells undergoing epithelial-mesenchymal transition (EMT), and the adoption of a cancer stem cell phenotype. The release of EVs is also involved in immunosuppression. Herein, we address different aspects by which EVs modulate the tumor microenvironment to become resistant to anticancer and antibody-based drugs, as well as the concept of the resistance-associated secretory phenotype (RASP).

Original languageEnglish
Article number47
Issue number3
Publication statusPublished - Mar 2020



  • Acidosis
  • Cell stress response
  • Drug resistance
  • Epithelial-mesenchymal transition (EMT)
  • Exosome
  • Extracellular vesicle (EV)
  • Heat shock protein (HSP)
  • Hypoxia
  • Oncosome
  • Resistance-associated secretory phenotype (RASP)
  • Tumor immunology

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Agricultural and Biological Sciences(all)

Cite this